BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 25284317)

  • 1. The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease.
    Schapansky J; Nardozzi JD; LaVoie MJ
    Neuroscience; 2015 Aug; 302():74-88. PubMed ID: 25284317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia.
    Maekawa T; Sasaoka T; Azuma S; Ichikawa T; Melrose HL; Farrer MJ; Obata F
    BMC Neurosci; 2016 Nov; 17(1):77. PubMed ID: 27903237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss.
    Ho DH; Nam D; Seo M; Park SW; Seol W; Son I
    Cells; 2022 Mar; 11(5):. PubMed ID: 35269482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
    Ho DH; Seol W; Son I
    Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils.
    Russo I; Kaganovich A; Ding J; Landeck N; Mamais A; Varanita T; Biosa A; Tessari I; Bubacco L; Greggio E; Cookson MR
    Neurobiol Dis; 2019 Sep; 129():67-78. PubMed ID: 31102768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of LRRK2 in Neurodegeneration of Parkinson Disease.
    Rui Q; Ni H; Li D; Gao R; Chen G
    Curr Neuropharmacol; 2018; 16(9):1348-1357. PubMed ID: 29473513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microglial LRRK2-mediated NFATc1 attenuates α-synuclein immunotoxicity in association with CX3CR1-induced migration and the lysosome-initiated degradation.
    Feng L; Lo H; Hong Z; Zheng J; Yan Y; Ye Z; Chen X; Pan X
    Glia; 2023 Sep; 71(9):2266-2284. PubMed ID: 37300531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
    Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
    J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
    Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
    Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain.
    Xu E; Boddu R; Abdelmotilib HA; Sokratian A; Kelly K; Liu Z; Bryant N; Chandra S; Carlisle SM; Lefkowitz EJ; Harms AS; Benveniste EN; Yacoubian TA; Volpicelli-Daley LA; Standaert DG; West AB
    Mol Neurodegener; 2022 Jan; 17(1):7. PubMed ID: 35012605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
    Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
    Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
    Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
    Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
    Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
    Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
    Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H
    Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
    Gillardon F; Schmid R; Draheim H
    Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease-derived α-synuclein assemblies combined with chronic-type inflammatory cues promote a neurotoxic microglial phenotype.
    Yildirim-Balatan C; Fenyi A; Besnault P; Gomez L; Sepulveda-Diaz JE; Michel PP; Melki R; Hunot S
    J Neuroinflammation; 2024 Feb; 21(1):54. PubMed ID: 38383421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies.
    Perry G; Zhu X; Babar AK; Siedlak SL; Yang Q; Ito G; Iwatsubo T; Smith MA; Chen SG
    Neurodegener Dis; 2008; 5(3-4):222-4. PubMed ID: 18322396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.
    Alegre-Abarrategui J; Ansorge O; Esiri M; Wade-Martins R
    Neuropathol Appl Neurobiol; 2008 Jun; 34(3):272-83. PubMed ID: 17971075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.